QurAlis

📍 Cambridge, United States🗓 Founded 2016👥 67 employees💰 Last funded Mar 2023
Biotechnology🌐 quralis.com
Website LinkedIn
At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will forever alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.
3
Total investors
1
Early stage
0
Mid stage
2
Late stage
2016
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2018–2023 · investors recorded per year
201812022120231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in QurAlis?
QurAlis has 3 investors on record on gritt.io, including 1 early-stage backers and 2 late-stage investors.
When did QurAlis last raise funding?
The most recent investment in QurAlis recorded on gritt.io was in March 2023.
When was QurAlis founded?
QurAlis was founded in 2016.
What industry is QurAlis in?
QurAlis operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is QurAlis based?
QurAlis is headquartered in Cambridge, United States.